

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CLARITY MEDICAL GROUP HOLDING LIMITED

清晰醫療集團控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1406)

ANNOUNCEMENT ON VACATION OF OFFICE OF AN EXECUTIVE DIRECTOR

This announcement is made by the board (the “**Board**”) of directors (the “**Directors**” and each a “**Director**”) of Clarity Medical Group Holding Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.51(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

Pursuant to Article 86(4) (“**Article 86(4)**”) of the articles of association of the Company, the office of a Director shall be vacated if, among other things, the Director suspends payment or compounds with his creditors.

The management of the Company had reported to the Board (i) the various outstanding legal proceedings and bankruptcy petition commenced against Dr. TSE Wai Yip (“**Dr. Tse**”), an executive Director, as announced by the Company on 12 February 2025 and 19 May 2025, (ii) the formal notices given by a Hong Kong governmental authority to the Company regarding outstanding payments owed by Dr. Tse, and (iii) other incidents suggesting Dr. Tse might have failed to settle outstanding payments.

The Board sought legal advice from Cayman Islands counsel regarding the interpretation of Article 86(4), which provides for the disqualification of a director who, among other things, suspends payment or compounds with their creditors. Additionally, the Company’s Hong Kong legal counsel advised the Board to take into account the totality of facts in considering the application of Article 86(4) to Dr. Tse. The Board was also informed on their fiduciary duties to uphold corporate governance standards.

Following such advice, a Board meeting was convened on 1 August 2025 to consider whether Dr. Tse's office as a Director should be declared to be vacated. On 1 August 2025 at 1:05 p.m., a majority of the Board resolved that Dr. Tse is disqualified as a Director and his office as a Director is vacated with immediate effect. Ms. CHENG Jessica and Mr. LO Tsz Hong voted against the declaration. Dr. Tse had to abstain from voting as the declaration involved his material interest. The other Directors voted for the declaration.

As Mr. WANG Can ("**Mr. Wang**", an independent non-executive Director) would be travelling when the Board meeting was held, he had appointed Mr. JIANG Bo ("**Mr. Jiang**", an executive Director) to be Mr. Wang's alternate Director to vote on the resolutions in relation to such declaration to be considered at the meeting. The appointment was not extended to other duties of Mr. Wang. Please refer to the announcement of the Company published on 9 September 2024 for the details of biography and the related information of Mr. Jiang. There is no service contract or letter of appointment between the Company and Mr. Jiang for his role as Mr. Wang's alternate Director for the meeting.

By order of the Board
CLARITY MEDICAL GROUP HOLDING LIMITED
WU Ting Yuk Anthony
Non-Executive Director and Chairman

Hong Kong, 1 August 2025

As at the date of this announcement, the Board comprises Mr. JIANG Bo, Mr. HUI Yung Chris and Mr. LO Tsz Hong as executive Directors, Mr. WU Ting Yuk Anthony as Chairman and non-executive Director and Ms. CHENG Jessica, Mr. WANG Can and Ms. CI Ying as independent non-executive Directors.